Checkpoint inhibitors and gastrointestinal immune-related adverse events

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 264-268

  Pernot, Simon ^a   Ramtohul, Toulsie ^a   Taieb, Julien ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

anticytotoxic T lymphocyte associated antigen 4; checkpoint inhibitors; colitis; gut microbiota

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HOST FACTOR; IMMUNE CHECKPOINT INHIBITOR; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; DOSE RESPONSE; DRUG SAFETY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; GASTROINTESTINAL DISEASE; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLITIS; CTLA-4 ANTIGEN; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASMS;

EID: 84965023560     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000292     Document Type: Review

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-2532.
4. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015; 372:2018-2028.
5. de Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7:95-101.
6. Daud A. Current and emerging perspectives on immunotherapy for melanoma. Semin Oncol 2015; 42 (Suppl 3):S3-S11.
7. Nancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3\+ regulatory T cells: a mechanistic explanation for ipilimumabinduced severe enterocolitis? Inflamm Bowel Dis 2012; 18:E1598-E1600.
8. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-750.
9. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.
10. Vé tizou M, Pitt JM, Daillè re R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350:1079-1084.
11. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015; 13:211.
12. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4: 560-575.
13. Weber JS, Minor D, D'angelo SP, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann Oncol 2014; 25 (Suppl 4).
14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
15. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013; 2013:857519.
16. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage IIImelanoma(EORTC18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-530.
17. Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-98.
18. Weber JS, Kä hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
19. Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015; 42:406-417.
20. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2:234-240.
21. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-2391.
22. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-571.